Practice Changing Studies in Hepato-Pancreato-Biliary Surgical Oncology (2020)

Activity Description

Alexander Parikh, MD, MPH, Vice Chair of the SSO Hepato-Pancreato-Biliary Disease Site Work Group moderates as Marcus Tan, MD, presents practice changing studies from 2019.

References

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet. 2019 March 25; 663–73: S1470-2045(18)30915-X

http://dx.doi.org/10.1016/

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.May 19, 2020 N Engl J Med 2020;382:1894-905; DOI: 10.1056/NEJMoa1915745

Evaluating Susceptibility to Pancreatic Cancer:ASCO Provisional Clinical Opinion.J Clin Oncol 37:153-164. November 20, 2018 by American Society of Clinical Oncology;DOI: 10.1200/JCO.18.01489

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/ PALB2 Mutation. January 24, 2020 ascopubs.org/journal/; DOI https://doi.org/10.1200/JCO.19.02931

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. June 2, 2019 N Engl J Med 2019;381:317-27. DOI: 10.1056/NEJMoa1903387

Summary


Availability:	On-Demand


Cost:	FREE


Credit Offered:	No Credit Offered